| Year |
Citation |
Score |
| 2021 |
Ma R, Zhang M, Oakman JM, Wang J, Zhu S, Zhao C, Hu Z, Buchanan NT. Eating disorders treatment experiences and social support: Perspectives from service seekers in mainland China. The International Journal of Eating Disorders. PMID 34101214 DOI: 10.1002/eat.23565 |
0.434 |
|
| 2010 |
Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. The Journal of Clinical Psychiatry. 71: 1336-43. PMID 20441724 DOI: 10.4088/Jcp.09M05114Gre |
0.398 |
|
| 2007 |
Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. The Journal of Clinical Psychiatry. 68: 288-95. PMID 17335328 DOI: 10.4088/Jcp.V68N0215 |
0.475 |
|
| 2006 |
Risko EF, Quilty LC, Oakman JM. Socially desirable responding on the web: investigating the candor hypothesis. Journal of Personality Assessment. 87: 269-76. PMID 17134335 DOI: 10.1207/s15327752jpa8703_08 |
0.31 |
|
| 2005 |
Eastwood JD, Smilek D, Oakman JM, Farvolden P, van Ameringen M, Mancini C, Merikle PM. Individuals with social phobia are biased to become aware of negative faces Visual Cognition. 12: 159-179. DOI: 10.1080/13506280444000175 |
0.37 |
|
| 2004 |
Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. The Journal of Clinical Psychiatry. 65: 1674-8. PMID 15641873 DOI: 10.4088/Jcp.V65N1213 |
0.518 |
|
| 2004 |
Van Ameringen M, Mancini C, Szechtman H, Nahmias C, Oakman JM, Hall GB, Pipe B, Farvolden P. A PET provocation study of generalized social phobia. Psychiatry Research. 132: 13-8. PMID 15546699 DOI: 10.1016/J.Pscychresns.2004.07.005 |
0.308 |
|
| 2004 |
Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H. Predictors of response in generalized social phobia: effect of age of onset. Journal of Clinical Psychopharmacology. 24: 42-8. PMID 14709946 DOI: 10.1097/01.Jcp.0000104909.75206.6F |
0.43 |
|
| 2003 |
Quilty LC, Van Ameringen M, Mancini C, Oakman J, Farvolden P. Quality of life and the anxiety disorders. Journal of Anxiety Disorders. 17: 405-26. PMID 12826089 DOI: 10.1016/S0887-6185(02)00225-6 |
0.368 |
|
| 2003 |
Oakman J, Gifford S, Chlebowsky N. A multilevel analysis of the interpersonal behavior of socially anxious people. Journal of Personality. 71: 397-434. PMID 12762421 DOI: 10.1111/1467-6494.7103006 |
0.368 |
|
| 2003 |
Oakman J, Van Ameringen M, Mancini C, Farvolden P. A confirmatory factor analysis of a self-report version of the Liebowitz Social Anxiety Scale. Journal of Clinical Psychology. 59: 149-61. PMID 12508338 DOI: 10.1002/Jclp.10124 |
0.394 |
|
| 2002 |
Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. The Journal of Clinical Psychiatry. 63: 981-4. PMID 12444810 DOI: 10.4088/Jcp.V63N1104 |
0.336 |
|
| 2000 |
Van Ameringen M, Mancini C, Farvolden P, Oakman J. The neurobiology of social phobia: from pharmacotherapy to brain imaging. Current Psychiatry Reports. 2: 358-66. PMID 11122982 DOI: 10.1007/S11920-000-0082-7 |
0.523 |
|
| 2000 |
van Ameringen M, Mancini C, Farvolden P, Oakman J. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opinion On Investigational Drugs. 9: 2215-31. PMID 11060802 DOI: 10.1517/13543784.9.10.2215 |
0.486 |
|
| 1999 |
Van Ameringen M, Mancini C, Farvolden P, Oakman J. Pharmacotherapy for social phobia: what works, what might work, and what does not work at all. Cns Spectrums. 4: 61-8. PMID 18438305 DOI: 10.1017/S1092852900012517 |
0.499 |
|
| 1997 |
Ameringen MV, Mancini C, Oakman J, Collins S. An open trial of nefazodone in the treatment of social phobia Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)86971-5 |
0.503 |
|
| 1997 |
Ameringen MV, Mancini C, Oakman J. Haloperidol treatment of trichotillomania: A pilot study Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)86965-X |
0.32 |
|
| Show low-probability matches. |